Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.

Trial Details

NCT ID

NCT03872661

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

IBI308
Bevacizumab
Pemetrexed
Carboplatin
Thoracic surgery

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Target population is unresectable stage III non-small cell lung cancer.
Written informed consent provided.
Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.
Male and female patients aged ≥18 years, \< 75 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →